Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery

Patent metadata

Field	Value
Publication number	US-11511016-B2
Application number	US-201916363471-A
Country	US
Kind code	B2
Filing date	Mar 25, 2019
Priority date	Oct 11, 2007
Publication date	Nov 29, 2022
Grant date	Nov 29, 2022

Abstract

The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).

First claim

The invention claimed is:

1. A porous scaffold comprising a polysaccharide selected from the group consisting of dextran, agar, pullulan, inulin, heparin, fucoidan, and mixtures thereof, crosslinked with trisodium trimetaphosphate, wherein the average pore size of the scaffold is between 1 and 500 μm, wherein the scaffold comprises pores of different sizes, and wherein the porosity is in the range from 4% to 50%, and wherein pores in the scaffold have an elongated shape, and are formed using a carbonate salt selected from the group consisting of ammonium carbonate, ammonium bicarbonate, sodium carbonate, sodium bicarbonate, calcium carbonate, and mixtures thereof and freeze drying, and wherein the pores are not formed by using a surfactant.

2. The porous scaffold of claim 1 , wherein the scaffold comprises pores of different shapes.

3. The porous scaffold of claim 1 , wherein the average pore size of the scaffold is between 150 and 350 μm.

4. The porous scaffold of claim 1 , wherein the scaffold comprises a polysaccharide selected from the group consisting of dextran, pullulan, fucoidan, and mixtures thereof.

5. The porous scaffold of claim 1 , wherein the scaffold comprises dextran and pullulan.

6. The porous scaffold of claim 1 , wherein the scaffold comprises pullulan and fucoidan.

7. The porous scaffold of claim 1 , wherein the scaffold is loaded with an amount of cells.

8. The porous scaffold according to claim 7 , wherein the cells are selected from the group consisting of yeast cells, mammalian cells, insect cells, and plant cells.

9. The porous scaffold according to claim 8 , wherein the mammalian cells are selected from the group consisting of chondrocytes, fibrochondrocytes, osteocytes, osteoblasts, osteoclasts, synoviocytes, bone marrow cells, epithelial cells, hepatocytes, mesenchymal cells, stromal cells, muscle cells, stem cells, embryonic stem cells, precursor cells derived from adipose tissue, peripheral blood progenitor cells, stem cells isolated from adult tissue, induced pluripotent stem cells (iPS cells), and genetically transformed cells.

10. A vascular substitute made with a scaffold of claim 1 .

11. Cartilage or bone implants made with a scaffold of claim 1 .

12. A controlled release system of an active agent made with a scaffold of claim 1 .

13. The porous scaffold of claim 1 wherein the freeze drying is performed after producing carbonate gas under acidic conditions from the carbonate salt selected from the group consisting of ammonium carbonate, ammonium bicarbonate, sodium carbonate, sodium bicarbonate, calcium carbonate, and mixtures thereof.

Assignees

• Inst Nat Sante Rech Med
• Univ Paris 7—Denis Diderot
• Univ Paris Cite

Inventors

• Le Visage Catherine
• Letourneur Didier

Classifications

• C08J2305/00

  Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00 · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• C08J9/08

  developing carbon dioxide · CPC title

• A61L27/20 Primary

  Polysaccharides · CPC title

• C08B37/0021

  Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran · CPC title